Gland Pharma Ltd
About
Gland Pharma is a leading pharmaceutical company that has grown over the years from a contract manufacturer [HK1] of small volume liquid parenteral products, to become one of the largest and fastest growing generic injectables manufacturing companies. The company has expanded its presence in 60+ countries, operating in India, China, the United States, Europe, and other international markets. Headquartered in Hyderabad, Gland Pharma operates manufacturing plants in Hyderabad, Visakhapatnam, and Dundigal in India, as well as in China through its subsidiary, Cenexi. A visionary, PVN Raju established Gland Chemicals in 1974 and Gland Pharma in 1978. In October 2017, Fosun Pharma acquired approximately 74 per cent of Gland Pharma which enhanced the company’s international market presence.
Featured In Fortune India Ranking
Financial Data 2024
Fortune India Coverage
Financial Data
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (INR Cr) | 5707 45.9% | 3912 -14.7% | 4588 18.5% | 3871 39.3% | 2779 23.9% | 2244 29.3% | 1735 18.4% | 1466 6.6% | 1375 35.2% | 1017 -5.5% | 1076 40.6% | 766 41.7% | 540 15.5% | 468 - |
| Net Operating Income (INR Cr) | 5665 56.29% | 3625 -17.64% | 4401 27.08% | 3463 31.51% | 2633 0.00% | 2044 26.19% | 1620 9.52% | 1479 9.74% | 1348 35.63% | 994 0.29% | 991 31.19% | 755 43.42% | 527 12.62% | 468 0.00% |
| Profit (INR Cr) | 772 -1.1% | 781 -35.5% | 1212 21.5% | 997 29.0% | 773 71.0% | 452 40.7% | 321 -22.4% | 414 31.9% | 314 49.9% | 209 -6.5% | 224 41.6% | 158 56.2% | 101 16.2% | 87 - |
| Assets (INR Cr) | 9274 16.4% | 7965 11.2% | 7164 21.2% | 5910 61.8% | 3654 26.8% | 2883 17.5% | 2454 14.9% | 2135 19.0% | 1794 15.0% | 1561 54.5% | 1011 37.7% | 734 36.6% | 537 29.9% | 414 - |
| Net Worth (INR Cr) | 8724 9.6% | 7959 11.2% | 7158 21.3% | 5903 61.9% | 3646 0.0% | 2862 18.7% | 2410 15.3% | 2090 24.6% | 1677 20.3% | 1394 67.2% | 834 36.7% | 610 35.0% | 452 28.9% | 350 0.0% |
| Employee Cost (INR Cr) | 1257 211.7% | 403 19.1% | 339 8.7% | 311 12.1% | 278 24.5% | 223 24.5% | 179 16.7% | 153 16.9% | 131 24.2% | 106 29.8% | 81 23.4% | 66 43.5% | 46 - | 0 - |
| Interest Cost (INR Cr) | 26 | 7 | 5 | 3 | 7 | 4 | 4 | 6 | 16 | 17 | 13 | 13 | 3 | 0 |
| Cash & Bank Balance (INR Cr) | 1839 | 3771 | 3093 | 3006 | 1325 | 753 | 651 | 533 | 273 | 316 | 77 | 91 | 84 | 64 |
| Total Debt (INR Cr) | 372 | 4 | 5 | 5 | 5 | 5 | 6 | 6 | 117 | 166 | 176 | 123 | 84 | 62 |
Key Financial Ratios
| PARAMETERS | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Profit As % Of Revenues | 13.5% | 20.0% | 26.4% | 25.8% | 27.8% | 20.1% | 18.5% | 28.2% | 22.8% | 20.6% | 20.8% | 20.7% | 18.7% | 18.6% |
| Profit As % Of Assets | 8.3% | 9.8% | 16.9% | 16.9% | 21.2% | 15.7% | 13.1% | 19.4% | 17.5% | 13.4% | 22.2% | 21.5% | 18.8% | 21.1% |
| Profit As % Of Networth | 8.9% | 9.8% | 16.9% | 16.9% | 21.2% | 15.8% | 13.3% | 19.8% | 18.7% | 15.0% | 26.9% | 25.9% | 22.4% | 24.9% |
| Interest Cost to EBITDA % | 2.0% | 0.8% | 0.4% | 0.3% | 0.8% | 0.5% | 0.8% | 1.0% | 3.3% | 5.3% | 3.7% | 5.5% | 2.1% | - |
| Debt to Equity Ratio | 0.04 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.12 | 0.21 | 0.20 | 0.19 | 0.18 |
| RONW | 9.3% | 10.3% | 18.6% | 20.9% | 21.2% | 17.1% | 14.3% | 22.0% | 20.4% | 18.8% | 31.0% | 29.8% | 25.2% | 24.9% |
| ROCE | 13.4% | 14.0% | 24.8% | 28.0% | 27.4% | 25.9% | 22.0% | 29.7% | 28.3% | 22.5% | 39.1% | 35.6% | 28.6% | 27.0% |